Small-Cell Lung Cancer - Pipeline Review, H2 2017

Small-Cell Lung Cancer - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2017, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.

Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 10, 49, 28, 2, 35 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Introduction 6
Small-Cell Lung Cancer - Overview 7
Small-Cell Lung Cancer - Therapeutics Development 8
Small-Cell Lung Cancer - Therapeutics Assessment5
Small-Cell Lung Cancer - Companies Involved in Therapeutics Development 39
Small-Cell Lung Cancer - Drug Profiles 76
Small-Cell Lung Cancer - Dormant Projects 714
Small-Cell Lung Cancer - Discontinued Products 720
Small-Cell Lung Cancer - Product Development Milestones 722
Appendix 741

List Of Tables

List of Tables
Number of Products under Development for Small-Cell Lung Cancer, H2 2017 22
Number of Products under Development by Companies, H2 2017 24
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 25
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 26
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 27
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 28
Number of Products under Development by Universities/Institutes, H2 2017 29
Products under Development by Companies, H2 2017 30
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 31
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 32
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 33
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 34
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 35
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 36
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 37
Products under Development by Universities/Institutes, H2 2017 38
Number of Products by Stage and Target, H2 2017 40
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 41
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 42
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 43
Number of Products by Stage and Mechanism of Action, H2 2017 45
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 46
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 47
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 48
Number of Products by Stage and Route of Administration, H2 2017 50
Number of Products by Stage and Molecule Type, H2 2017 52
Small-Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2017 53
Small-Cell Lung Cancer - Pipeline by AbbVie Inc, H2 2017 54
Small-Cell Lung Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2017 54
Small-Cell Lung Cancer - Pipeline by Advantagene Inc, H2 2017 55
Small-Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017 55
Small-Cell Lung Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2017 55
Small-Cell Lung Cancer - Pipeline by Alchemia Ltd, H2 2017 56
Small-Cell Lung Cancer - Pipeline by Amgen Inc, H2 2017 56
Small-Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2017 57
Small-Cell Lung Cancer - Pipeline by Aposense Ltd, H2 2017 57
Small-Cell Lung Cancer - Pipeline by Aprea AB, H2 2017 58
Small-Cell Lung Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017 58
Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H2 2017 58
Small-Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017 59
Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2017 59
Small-Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017 60
Small-Cell Lung Cancer - Pipeline by Bayer AG, H2 2017 61
Small-Cell Lung Cancer - Pipeline by BeiGene Ltd, H2 2017 61
Small-Cell Lung Cancer - Pipeline by Beta Pharma Inc, H2 2017 61
Small-Cell Lung Cancer - Pipeline by BioLineRx Ltd, H2 2017 62
Small-Cell Lung Cancer - Pipeline by Bionomics Ltd, H2 2017 62
Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017 63
Small-Cell Lung Cancer - Pipeline by Celgene Corp, H2 2017 64
Small-Cell Lung Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017 64
Small-Cell Lung Cancer - Pipeline by Checkpoint Therapeutics Inc, H2 2017 65
Small-Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2017 65
Small-Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017 66
Small-Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2017 66
Small-Cell Lung Cancer - Pipeline by Eli Lilly and Co, H2 2017 67
Small-Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 67
Small-Cell Lung Cancer - Pipeline by G1 Therapeutics Inc, H2 2017 68
Small-Cell Lung Cancer - Pipeline by Genzyme Corp, H2 2017 68
Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017 69
Small-Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H2 2017 69
Small-Cell Lung Cancer - Pipeline by Immunomedics Inc, H2 2017 70
Small-Cell Lung Cancer - Pipeline by Incyte Corp, H2 2017 70
Small-Cell Lung Cancer - Pipeline by Innovation Pharmaceuticals Inc, H2 2017 71
Small-Cell Lung Cancer - Pipeline by Ipsen SA, H2 2017 71
Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H2 2017 72
Small-Cell Lung Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2017 72
Small-Cell Lung Cancer - Pipeline by Lindis Biotech GmbH, H2 2017 72
Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2017 73
Small-Cell Lung Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 73
Small-Cell Lung Cancer - Pipeline by MedImmune LLC, H2 2017 74
Small-Cell Lung Cancer - Pipeline by Merck & Co Inc, H2 2017 75
Small-Cell Lung Cancer - Pipeline by Merck KGaA, H2 2017 75
Small-Cell Lung Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 76
Small-Cell Lung Cancer - Pipeline by Mirati Therapeutics Inc, H2 2017 76
Small-Cell Lung Cancer - Pipeline by Moderna Therapeutics Inc, H2 2017 77
Small-Cell Lung Cancer - Pipeline by MolMed SpA, H2 2017 77
Small-Cell Lung Cancer - Pipeline by Mologen AG, H2 2017 78
Small-Cell Lung Cancer - Pipeline by Mundipharma International Ltd, H2 2017 78
Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H2 2017 78
Small-Cell Lung Cancer - Pipeline by NewLink Genetics Corp, H2 2017 79
Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co Ltd, H2 2017 79
Small-Cell Lung Cancer - Pipeline by Novartis AG, H2 2017 80
Small-Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 81
Small-Cell Lung Cancer - Pipeline by Pfizer Inc, H2 2017 81
Small-Cell Lung Cancer - Pipeline by Pharma Mar SA, H2 2017 82
Small-Cell Lung Cancer - Pipeline by Plexxikon Inc, H2 2017 82
Small-Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals Inc, H2 2017 82
Small-Cell Lung Cancer - Pipeline by Rafael Pharmaceuticals Inc, H2 2017 83
Small-Cell Lung Cancer - Pipeline by Recombio SL, H2 2017 83
Small-Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2017 84
Small-Cell Lung Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 84
Small-Cell Lung Cancer - Pipeline by Sunshine Biopharma Inc, H2 2017 85
Small-Cell Lung Cancer - Pipeline by Syros Pharmaceuticals Inc, H2 2017 85
Small-Cell Lung Cancer - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 86
Small-Cell Lung Cancer - Pipeline by Tarveda Therapeutics Inc, H2 2017 86
Small-Cell Lung Cancer - Pipeline by Tesaro Inc, H2 2017 86
Small-Cell Lung Cancer - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017 87
Small-Cell Lung Cancer - Pipeline by Trovagene Inc, H2 2017 87
Small-Cell Lung Cancer - Pipeline by United Therapeutics Corp, H2 2017 88
Small-Cell Lung Cancer - Pipeline by Verastem Inc, H2 2017 88
Small-Cell Lung Cancer - Pipeline by ViiV Healthcare UK Ltd, H2 2017 89
Small-Cell Lung Cancer - Pipeline by Xencor Inc, H2 2017 89
Small-Cell Lung Cancer - Dormant Projects, H2 2017 728
Small-Cell Lung Cancer - Dormant Projects, H2 2017 (Contd..1), H2 2017 729
Small-Cell Lung Cancer - Dormant Projects, H2 2017 (Contd..2), H2 2017 730
Small-Cell Lung Cancer - Dormant Projects, H2 2017 (Contd..3), H2 2017 731
Small-Cell Lung Cancer - Dormant Projects, H2 2017 (Contd..4), H2 2017 732
Small-Cell Lung Cancer - Dormant Projects, H2 2017 (Contd..5), H2 2017 733
Small-Cell Lung Cancer - Discontinued Products, H2 2017 734
Small-Cell Lung Cancer - Discontinued Products, H2 2017 (Contd..1), H2 2017 735

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available